First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China; ; The Collaborative Research (CORE) Group, Sydney, Australia.
First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China;
Hepatobiliary Surg Nutr. 2013 Jun;2(3):148-55. doi: 10.3978/j.issn.2304-3881.2013.06.06.
Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis, and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results.
Electronic databases updated to June 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF overexpression and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed.
We performed a meta-analysis of 14 studies that evaluated the correlation between VEGF overexpression and survival in patients with HCC. Combined hazard ratios suggested that VEGF overexpression had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.42, 95% confidence interval (CI): 1.42-1.7], but not disease free survival (DFS) (HR=1.13, 95% CI: 0.89-1.38) in patients with HCC. No significant heterogeneity (P=0.949) was observed among 9 studies for OS, however significant heterogeneity (P=0.008) was observed among 11 studies for DFS.
VEGF overexpression indicates a poor prognosis for patients with HCC.
血管内皮生长因子（VEGF）被认为是血管生成的主要介质，并且与癌发生和转移有关。许多研究都检查了 VEGF 过表达与肝细胞癌（HCC）患者临床结果之间的关系，但结果却相互矛盾。
检索了截至 2013 年 6 月的电子数据库，以查找相关研究。对定量评估 VEGF 过表达与 HCC 患者生存之间关系的合格研究进行了荟萃分析。汇总并定量分析了生存数据。
我们对 14 项评估 VEGF 过表达与 HCC 患者生存相关性的研究进行了荟萃分析。综合危险比表明，VEGF 过表达对总生存期（OS）有不利影响[危险比（HR）=1.42，95%置信区间（CI）：1.42-1.7]，但对无病生存期（DFS）（HR=1.13，95% CI：0.89-1.38）无影响。9 项研究的 OS 无显著异质性（P=0.949），但 11 项研究的 DFS 有显著异质性（P=0.008）。
VEGF 过表达提示 HCC 患者预后不良。
